Month: July 2025

Introduction and Objective: Published data support use of 14 days of CGM to provide reliable estimates of CGM metrics, including the glucose management indicator (GMI) to estimate A1c. We examined relationships between A1c and GMI in AYA.Methods: AYA with T1D, aged 14-25 years, wore Dexcom CGM (G6 or G7) for up to 90 days prior […]

Introduction and Objective: Thyroid Hormone Interacting Protein 10 (TRIP10), also known as CDC42-Interacting Protein 4 (CIP4) is required for insulin mediated translocation of GLUT4 to the plasma membrane in response to insulin signaling. However, no monogenic forms of diabetes have been attributed to this gene. The Rare and Atypical DIAbetes NeTwork (RADIANT) is a multicenter […]

Introduction and Objective: Loss-of-function mutations in the exocrine pancreatic enzyme chymotrypsin-like elastase (CELA2A) are associated with metabolic syndrome and diabetes. CELA2A is a ubiquitously expressed protein that enters circulation and enhances both insulin secretion and sensitivity. Mice with global deletion of Cela2a exhibit impaired glucose-stimulated insulin secretion, accompanied by reduced pancreatic islet size and number, […]

Introduction and Objective: The Omnipod 5 App for iPhone allows users to interact with the Omnipod 5 System and discreetly manage their diabetes via personal smartphone. This study evaluated real-world bolusing behaviors in adolescent and young adult Omnipod 5 users with T1D in the US switching to the iPhone app.Methods: A retrospective analysis of CGM […]

Introduction and Objective: We applied AI-based SHAP (Shapley Additive Explanations) clustering to identify high-risk individuals for diabetes in a population-based Korean cohort.Methods: KoGES data were analyzed, comparing individuals who developed type 2 diabetes (T2DM) within five years to those who remained diabetes-free. A predictive model utilizing transfer learning and intermediate fusion was used. Among 27,745 […]

Introduction and Objective: MiniMedTM 780G (MM780G) advanced hybrid closed loop (AHCL) therapy with the Guardian™ 4 sensor demonstrated significantly improved A1C, increased time in range (%TIR, 70-180mg/dL) and tight range (%TITR, 70-140mg/dL), with no increase in time below range (%TBR, <70mg/dL), in PwT2D.1 Herein, we report on system use with the new, disposable, all-in-one Simplera […]

Introduction and Objective: CGM is standard of care for people living with T1D; barriers to sustaining CGM use persist. Less is known about factors leading to non-use following initial CGM uptake.Methods: This qualitative study explored experiences of adults (ages 18-50) with T1D in a CGM uptake randomized controlled trial who received 3 months of CGM […]

Introduction and Objective: Cellular senescence is a stress response marked by the upregulation of antiapoptotic pathways, loss of function, and secretome remodeling (SASP). Pancreatic β-cells undergo senescence with age and insulin resistance, while their targeted removal improves glucose homeostasis, demonstrating the role of β-cell senescence in diabetes progression. However, β-cell senescence can also promote β-cell […]

Introduction and Objective: Type two diabetes (T2D) is a leading cause of chronic renal disease (CKD). Despite strong links between T2D, CKD, and cardiovascular disease (CV), the incidence and timing of major arrhythmias in this high-risk population remains unclear. This study examines the incidence, timing, and risk associated with major arrhythmias in T2D-CKD patients.Methods: We […]

Introduction and Objective: Insulin pumps are beneficial for people with type 1 diabetes (T1D). However, the time required to initiate pump therapy after the decision to start remains unclear. This study quantifies the time from decision to pump start (TTPS).Methods: This retrospective study included individuals with T1D at an academic diabetes center who decided to […]